Cancer of unknown primary: A population-based analysis of temporal change and socioeconomic disparities

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1318-1324

  Urban, D ^a   Rao, A ^a   Bressel, M ^a   Lawrence, Y R ^b,c   Mileshkin, L ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b SHEBA MEDICAL CENTER   (Israel)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

neoplasms; unknown primary; epidemiology; health status disparities; SEER program; trends

Indexed keywords

ADENOCARCINOMA; ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; EDUCATIONAL STATUS; EUROPEAN AMERICAN; FEMALE; GROUPS BY AGE; HEALTH DISPARITY; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NEUROENDOCRINE TUMOR; NEWBORN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; SCHOOL CHILD; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREND STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTHCARE DISPARITIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; SEER PROGRAM; SOCIOECONOMIC FACTORS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84883743339     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.386     Document Type: Article

References (33)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN (1995) Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13(8): 2094-2103.
2. Al-Brahim N, Ross C, Carter B, Chorneyko K (2005) The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol 9(2): 77-80. (Pubitemid 40460741)
3. Boyland L, Davis C (2008) Patients' experiences of carcinoma of unknown primary site: dealing with uncertainty. Palliat Med 22(2): 177-183. (Pubitemid 351597278)
4. Bridgewater J, Van Laar R, Floore A, Veer LVT (2008) Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 98(8): 1425-1430. (Pubitemid 351543580)
5. Brustugun OT, Helland Å (2013) Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol; e-pub ahead of print 4 April 2013.
6. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760): 127-138.
7. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116(3): 544-573.
8. Fong T, Govindan R, Morgensztern D (2008) Cancer of unknown primary. J Clin Oncol 2008 ASCO Ann Meet Proc 26(15S): 22159.
9. Gould MK, Schultz EM, Wagner TH, Xu X, Ghaus SJ, Wallace RB, Provenzale D, Au DH (2011) Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study. J Thorac Oncol 6(5): 875-883.
10. Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 23(2): 298-304.
11. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. J Clin Oncol 31(2): 217-223.
12. Hemminki K, Bevier M, Hemminki A, Sundquist J (2012) Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 23(7): 1854-1863.
13. Kim C, Hannouf M, Brackstone M, Winquist E, Zaric G (2013) Identification of the occult tumor in cancer of unknown primary (CUP): a priority based on histology. J Clin Oncol 31(suppl; abstr 1605).
14. Koepsell T, Weiss N (2003) Epidemiologic Methods: Studying The Occurence Of Illness. Oxford University Press: New York, NY, USA.
15. Kwee TC, Kwee RM (2009) Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 19(3): 731-744.
16. Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha SY, Lee KB, Kang JH, Park BJ (2013) Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer 108(1): 39-48.
17. Luke C, Koczwara B, Karapetis C, Pittman K, Price T, Kotasek D, Beckmann K, Brown MP, Roder D (2008) Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health 32(4): 383-389.
18. Merrill RM, Merrill AV, Mayer LS (2000) Factors associated with no surgery or radiation therapy for invasive cervical cancer in Black and White women. Ethn Dis 10(2): 248-256.
19. Morris GJ, Greco FA, Hainsworth JD, Engstrom PF, Scialla S, Jordan 3rd WE, Thomas LC (2010) Cancer of unknown primary site. Semin Oncol 37(2): 71-79.
20. Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA (2011) American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol 29(28): 3816-3824.
21. Muir C (1995) Cancer of unknown primary site. Cancer 75(1 Suppl): 353-356.
22. Muir C (2006) Cancer of unknown primary site. Cancer 75(S1): 353-356.
23. Oien KA (2009) Pathologic evaluation of unknown primary cancer. Semin Oncol 36(1): 8-37.
24. Pavlidis N, Pentheroudakis G (2010) Cancer of unknown primary site: 20 questions to be answered. Ann Oncol 21(Suppl 7): vii303-vii307.
25. Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379(9824): 1428-1435.
26. Rachet B, Woods L, Mitry E, Riga M, Cooper N, Quinn M, Steward J, Brenner H, Estève J, Sullivan R (2008) Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 99: S2-S10.
27. Randén M, Rutqvist L-E, Johansson H (2009) Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007.Acta Oncol 48(6): 915-920.
28. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR (2007) The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109(2): 292-299. (Pubitemid 46116455)
29. Shu X, Sundquist K, Sundquist J, Hemminki K (2012) Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev 21(3): 281-288.
30. Singh G, Miller B, Hankey B, Edwards B (2003) Area Socioeconomic Variations in U.S. Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975-1999. National Cancer Institute: Bethesda, MD, USA, NIH Publication No. 03-5417.
31. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2009). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on November 2011 submission, www.seer.cancer.gov.
32. Tracey E, Glass P, Roder D, Currow D, Jelfs P, Bishop J (2008) Unknown Primary Cancer in New South Wales. Cancer Institute NSW: New South Wales, Sydney, Australia.
33. Wedding U, Lichtman SM (2013) Treatment decisions and medical treatment of cancer in elderly patients. In Drug Therapy for the Elderly. Springer: Vienna, pp 229-247.